Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence to precision medicine, has launched its first research study in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global nonprofit foundation dedicated to advancing treatments for follicular lymphoma (FL). This multi-year initiative marks a significant milestone as Tempus’ first formal partnership with a nonprofit foundation and aims to create a comprehensive, multi-omic dataset to drive innovation in FL research and personalized therapy. The study will enroll patients with FL, the second most common type of non-Hodgkin lymphoma in the U.S., accounting for 10–20% of cases. Despite treatment advances, approximately 20% of patients experience disease progression within two years of initial chemoimmunotherapy, and five-year overall survival remains at just 50%. The research will leverage cutting-edge technologies including next-generation sequencing, proteomics, and methylation analysis to generate deep molecular profiles of patient samples. By integrating these data with real-world clinical information, the project seeks to uncover new biomarkers, understand disease biology, and support the development of more effective, individualized therapies. Kate Sasser, PhD, Tempus’ Chief Scientific Officer, emphasized the transformative potential of the collaboration, stating that the study will deliver a uniquely rich and actionable dataset to help researchers gain deeper insights into FL. “This comprehensive approach will provide researchers with a uniquely deep and actionable understanding of follicular lymphoma, paving the way for new discoveries and personalized treatment strategies,” she said. David McCullagh, Managing Director of IFLI, highlighted the importance of the partnership, noting that Tempus was selected for its advanced capabilities in molecular profiling and data science. “We are grateful for the collaboration from our network that brought this vision to life,” he said. “Together, we aim to create a transformative dataset that integrates real-world clinical insights with advanced testing and analytics to uncover the biological drivers of FL and enable more personalized therapies that improve patient outcomes globally.” The study builds on an existing collaboration between Tempus and IFLI to create a centralized, real-world FL data library. By combining clinical outcomes with high-dimensional molecular data, the project supports a data-driven approach to drug discovery and validation, including the development of whole genome sequencing methods. The resulting dataset is expected to become a critical resource for researchers worldwide, accelerating the pace of innovation in FL care. Tempus, which operates one of the world’s largest libraries of multimodal health data, uses AI to make this information accessible and actionable for physicians and researchers. The company’s platform enables learning from collective patient data, helping to inform treatment decisions and drive the development of optimal therapeutics. The goal is to ensure that every patient benefits from the knowledge gained from those who came before. The partnership reflects a growing trend in precision medicine, where public-private collaborations and data sharing are key to advancing research. IFLI’s mission to accelerate innovation through grants, partnerships, and venture philanthropy aligns with Tempus’ commitment to using technology to improve patient outcomes. While the study is forward-looking, it is grounded in a shared mission to address unmet needs in FL. The project’s success could set a precedent for future collaborations between AI-driven health technology companies and nonprofit research foundations, particularly in rare or underfunded disease areas. This initiative underscores the power of combining real-world data, advanced analytics, and patient-centered research to transform the future of cancer care.